


TEMPUS | ONCOLOGY

Clinic guide to Tempus tests

Your comprehensive guide to understanding our molecular test offerings, interpreting our test names, and streamlining the ordering process.

TEST NAME	TURNAROUND TIME	CLINIC SPECIMEN NEEDED	SPECIMEN COLLECTION KIT(S)
xT CDx **DNA seq** *T is for Tissue*	**~9 days** after specimen receipt	Blood or Saliva *Tempus requests tissue specimen from Pathology.*	
xR **RNA seq** *R is for RNA*	**~9 days** after specimen receipt	**None from clinic** *Tempus requests tissue specimen from pathology.*	N/A
xF+ **liquid biopsy** *F is for Fluid*	**~6 days** after specimen receipt	Blood	
xT **and/or** xR **for hematologic malignancies**	**~10-21 days** after specimen receipt, and when xT and xR are ordered in combination	Blood or Bone Marrow Aspirate *The Tempus kit for hematologic malignancies is orange.*	
CancerNext® or CancerNext-*Expanded*®, +RNAinsight®, BRCAplus® hereditary cancer testing *Powered by Ambry Genetics®, a Tempus company.*	**CancerNext® or CancerNext-*Expanded*®:** **~5-14 days** after specimen receipt **BRCAplus®: ~4-7 days** after specimen receipt	Blood DNA Only or Saliva DNA Only or Blood DNA & RNA *Draw EDTA blood tube first, then draw PAXgene® blood tube last if ordering +RNAinsight.*	 *Tempus offers **three** hereditary kits. Each kit displays the specimen type: **DNA (blood), DNA (saliva),** or **DNA + RNA (blood).***
xM **MRD for CRC** *M is for Monitoring*		Blood *The Tempus kit for MRD blood collection is Royal Blue-colored and has the xM badge on the front, sides, and top.*	
xM **NeXT Personal® Dx** **for solid tumors** *M is for Monitoring*	**~3-4 weeks** for baseline, **~7-8 days** for subsequent	Blood *Tempus requests tissue specimen from Pathology.*	

FINANCIAL ASSISTANCE

tempus.co/patient-forms

ORDERING A TEST

tempus.co/test-ordering

ORDERING SUPPORT

tempus.co/care-team-guide

MOBILE PHLEBOTOMY

tempus.co/phlebotomy

Questions?

Please contact your Tempus Representative or email support@tempus.com.

xT CDx is a qualitative Next Generation Sequencing (NGS)-based in vitro diagnostic device intended for use in the detection of substitutions (single nucleotide variants (SNVs) and multi-nucleotide variants (MNVs)) and insertion and deletion alterations (INDELs) in 648 genes, as well as microsatellite instability (MSI) status, using DNA isolated from Formalin-Fixed Paraffin Embedded (FFPE) tumor tissue specimens, and DNA isolated from matched normal blood or saliva specimens, from previously diagnosed cancer patients with solid malignant neoplasms.The test is intended as a companion diagnostic (CDx) to identify patients who may benefit from treatment with the targeted therapies listed in the Companion Diagnostic Indications table in accordance with the approved therapeutic product labeling. Additionally, xT CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with previously diagnosed solid malignant neoplasms. Genomic findings other than those listed in the Companion Diagnostic Indications table are not prescriptive or conclusive for labeled use of any specific therapeutic product. xT CDx is a single-site assay performed at Tempus AI, Inc., Chicago, IL. For the complete xT CDx label, including companion diagnostic indications and important risk information, please visit tempus.com/xt-cdx-label/

TEMPUS | ONCOLOGY

This is AI-enabled precision medicine.
This is the future of healthcare.

tempus.com/oncology/